• Relative Infarct Transmurality [ Time Frame: Measured during Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging within 3 months after inclusion and before ICD implantation ]
  Percentage Relative Infarct Transmurality (RIT = transmural infarct mass / total infarct mass) obtained from LGE-CMR
• appropriate ICD intervention (shock or ATP) [ Time Frame: Until the 24 month follow-up ]
  assessment whether patient had appropriate ICD intervention (shock or ATP) or not during 24 months follow-up. ICD interventions will be labeled appropriate or non-appropriate by an independent endpoint committee.

• LV function (EF) [ Time Frame: Baseline ]
  Left Ventricular function (Ejection Fraction in %) measured during LGE-CMR at baseline before ICD implantation
• LV mass [ Time Frame: Baseline ]
  LV mass measured during LGE-CMR at baseline before ICD implantation
• total infarct mass [ Time Frame: Baseline ]
  total infarct mass measured during GGE-CMR at baseline before ICD implantation
• transmural infarct mass [ Time Frame: Baseline ]
  transmural infarct mass measured during LGE-CMR at baseline before ICD implantation
• mean Heart Rate (HR) [ Time Frame: Baseline ]
  mean HR measured by 24-hrs Holter
• Day and night HR [ Time Frame: baseline ]
  Day and night HR measured by 24-hrs Holter
• spontaneous episodes of atrial and ventricular arrhythmias [ Time Frame: baseline ]
  number of spontaneous episodes of atrial and ventricular arrhythmias measured by 24-hrs Holter
• heart rate variability (SDNN: Standard deviation of consecutive normal-to-normal intervals) [ Time Frame: baseline ]
  heart rate variability (SDNN) measured by 24-hrs Holter
• HR [ Time Frame: baseline ]
  HR on 12 lead ECG
• rhythm [ Time Frame: baseline ]
  rhythm on 12 lead ECG
• QRS width [ Time Frame: baseline ]
  QRS width on 12 lead ECG
• serum sodium and potassium [ Time Frame: baseline ]
  concentration of serum sodium and potassium (in mmol/l ) (blood sample)
• serum creatinine [ Time Frame: baseline ]
  concentration of serum creatinine (in umol/l) (blood sample)
• uric acid [ Time Frame: baseline ]
  concentration of uric acid (in mmol/l) (blood sample)
• albumin [ Time Frame: baseline ]
  concentration of albumin (in g/l) (blood sample)
• HbA1c (Hemoglobin A1c) [ Time Frame: baseline ]
  concentration HbA1c (mmol/mol) (blood sample)
• NT-proBNP (N-terminal pro-hormone Brain Natriuretic Peptide) [ Time Frame: baseline ]
  concentration NT-proBNP (in pg/ml) (blood sample)
• hsTNT/I (high sensitive Troponin-T/I) [ Time Frame: baseline ]
  concentration hsTNT/I (in ng/ml) (blood sample)
• aldosterone [ Time Frame: baseline ]
  concentration aldosterone (in pmol/l) (blood sample)
• incidence of hypertension [ Time Frame: baseline ]
  Baseline clinical demographics: hypertension in clinical history
• incidence of diabetes [ Time Frame: baseline ]
  Baseline clinical demographics: diabetes in clinical history
• incidence of hypercholesterolemia [ Time Frame: baseline ]
  Baseline clinical demographics: hypercholesterolemia in clinical history
• PVC/hr: Premature ventricular contraction per hour [ Time Frame: baseline ]
  PVC/hr: Premature ventricular contraction per hour on 24hrs Holter

Design: PARCADIA is a prospective non-randomized non-interventional multi-center clinical investigation in Europe. Patients with depressed LV (left ventricular) function assessed on local standards, of ischemic origin and on chronic optimal medical therapy will be selected according to inclusion and exclusion criteria, implanted with an ICD after executing baseline investigations and prospectively followed up for minimal 24 months and until the termination of the clinical investigation.

General objective: analysis of baseline risk factors to identify predictors for appropriate ICD intervention in patients with ischemic cardiomyopathy receiving an ICD for primary prevention (MADIT II population).

Hypothesis: The primary alternative hypothesis states that the mean relative infarct transmurality (RIT) is different in patients with (RITshock or ATP (Anti Tachy Pacing)) and without (RITno shock or ATP )appropriate ICD intervention, i.e. shock or ATP.

• Null hypothesis (H0): RITshock or ATP = RITno shock or ATP
• Alternative hypothesis (Ha): RITshock or ATP ≠ RITno shock or ATP

Sample size: 200 patients.

Follow-up: Enrolment visit, pre implant screening, ICD implantation, pre-hospital discharge visit, and follow-up (FUP) visits at 2, 6, 12, 18, 24 months including home monitoring. Additional routine FUP every 6 months until study termination after last enrolled patient has completed 2 years FUP.

Rationale: Implantation of an ICD as primary prevention therapy is indicated according to the current guidelines based on the low LVEF (Left Ventricular Ejection Fraction) as it was shown to significantly reduce mortality. Although of proven efficacy, ICD therapy is associated with survival benefit in only a small fraction of patients. It is estimated that 18 patients would have to receive an ICD to save one life, resulting in a huge burden on national health systems. Moreover, only about one quarter of all guideline eligible primary prevention ICD patients receive appropriate shocks. The above considerations support the need for an effective risk-stratification method to identify patients that benefit most (or least) from this therapy. Evaluation of ventricular anatomy and function by imaging techniques has become more important since this provides information on the substrate (myocardial scar) and trigger of life-threatening ventricular arrhythmias. Besides accurate estimation of left and right ventricular volumes and functions, Late Gadolinium Enhanced Cardiac Magnetic Resonance (LGE-CMR) imaging has a very high sensitivity to detect myocardial scar. Quantification of scar characteristics by cardiac MRI might be useful for the prediction of future arrhythmic events in patients with ischemic cardiomyopathy. However evidence is conflicting and published papers are hampered by limited patient numbers and can only be regarded in the light of generating hypothesis. The PARCADIA clinical investigation will explore the potential of cardiac MRI as a predictor for appropriate ICD intervention in a multicenter setting.

PARCADIA is a prospective non-randomized non-interventional multi-center clinical investigation in Europe. Patients with depressed LV (Left Ventricular) function assessed on local standards, of ischemic (at least 40 days post-MI (myocardial infarction) or 3 months post revascularization) origin and on chronic optimal medical therapy will be selected according to inclusion and exclusion criteria, implanted with an ICD after executing baseline investigations and prospectively followed up for minimal 24 months and until the termination of the clinical investigation

General objective: analysis of baseline risk factors to identify predictors for appropriate ICD intervention in patients with ischemic cardiomyopathy receiving an ICD for primary prevention (MADIT II population).

The primary objective of the clinical investigation is to determine whether there is a relationship between appropriate ICD intervention (shock or ATP) and the Relative Infarct Transmurality (RIT) obtained from Late Gadolinium Enhanced Cardiac Magnetic Resonance (LGE-CMR) imaging in patients with ischemic cardiomyopathy, receiving an ICD for primary prevention.

Methodology: Screening: (within 6 months before enrolment) patients with LV depressed function due to Ischemic Cardiomyopathy with an indication for primary prevention ICD implantation according to ESC (European Society of Cardiology) guidelines or local standards will be screened within 6 months before enrolment.

pre implant diagnostics: within 3 months after enrolment LGE-CMR imaging, 24h holter, 12-lead ECG, will be performed and biochemical markers will be obtained.

ICD implantation: Implantation of a Lumax 540 single/dual chamber ICD or successor withiin 3 months after enrolment. The ICD will be programmed according to protocol.

Pre-hospital discharge an ICD interrogation wil be performed. Follow-up (FUP) visits at: 2, 6, 12, 18, 24 months with inclusion of standard 12-lead ECG, ICD check-up and cardiologist visit in the outpatient clinic. Additional routine FUP every 6 months until study termination after last enrolled patient has completed 2 years FUP.

• ICD
• Cardiomyopathy Ischemic
• Primary Prevention

Inclusion Criteria:

• Patient with ischemic cardiomyopathy indicated for a de novo ICD implantation for primary prevention, according to ESC guidelines or local standards (MADIT II population)
• Written informed consent / willingness and ability to comply with the protocol

Exclusion Criteria:

• Contraindication for MRI
• Severe renal dysfunction (stage 4 or 5) resulting in contra-indication for the admission of gadolinium during MRI (See Appendix A for more details)
• Indication for secondary prevention ICD implantation
• Class I indication for cardiac resynchronization therapy
• Heart failure with New York Heart Association functional class IV
• LV ejection fraction >40%
• Age <18 years and >85 years
• Women that are pregnant, lactating or planning to become pregnant
• Participating in any other clinical trial with active intervention(s) during the course of this study
• Life expectancy less than 1 year